Numerous strategies have been evaluated to promote the anti-tumor potential of macrophages, such as the use of JAK1/2 inhibitor, ruxolitinib, to reverse M2 polarization in favor of the M1 phenotype in in vitro and in vivo MM models [30]. This evidence concerns the gene JAK1 and Miyoshi myopathy.